Prevention by blockade of angiotensin subtype1-receptors of the development of genetic hypertension but not its heritability

P. Madeddu, V. Anania, M. V. Varoni, P. P. Parpaglia, M. P. Demontis, M. C. Fattaccio, D. Palomba, D. Pollock, N. Glorioso

Research output: Contribution to journalArticle

Abstract

1. We determined whether early inhibition of angiotensin II subtype, (AT1) receptors by the newly synthesized nonpeptidic antagonist, A-81988, can attenuate the development of hypertension in spontaneously hypertensive rats (SHR) and if the altered blood pressure phenotype can be passed on to the subsequent generation, not exposed to the antagonist. 2. Pairs of SHR were mated while drinking tap water or A-81988 in tap water, and the progeny was maintained on the parental regimen until 14 weeks of age. At this stage, A-81988-treated rats showed lower systolic blood pressure and body weight values (136 ± 5 versus 185 ± 4 mmHg and 247 ± 4 versus 283 ± 4 g in controls, P <0.01), while heart rate was similar. In addition, mean blood pressure was reduced (101 ± 7 versus 170 ± 7 mmHg in controls, P <0.01), and the presser responses to intravenous or intracerebroventricular angiotensin II were inhibited by 27 and 59%, respectively. Heart/body weight ratio was smaller in A-81988-treated rats (3.2±0.1 versus 3.8±0.1 in controls, P<0.01). 3 The antihypertensive and antihypertrophic effect of A-81988 persisted in rats removed from therapy for 7 weeks (systolic blood pressure: 173±4 versus 220±4 mmHg, heart/body weight ratio: 3.41±0.1 versus 4.1±0.1 in controls at 21 weeks of age, P<0.01 for both comparisons), whereas the cardiovascular hypertensive phenotype was fully expressed in the subsequent generation that was maintained without treatment. 4. These results indicate that chronic blockade of angiotensin AT1-receptors attenuates the development of hypertension in SHR but it does not prevent the transmission of hypertension to the following generation. Thus, heritability of the SHR's hypertensive trait is not affected by pharmacological manipulation of the cardiovascular phenotype.

Original languageEnglish
Pages (from-to)557-562
Number of pages6
JournalBritish Journal of Pharmacology
Volume115
Issue number4
Publication statusPublished - 1995

Fingerprint

A 81988
Angiotensin Receptors
Blood Pressure
Hypertension
Inbred SHR Rats
Body Weight
Phenotype
Angiotensin II
Angiotensin Type 1 Receptor
Drinking Water
Antihypertensive Agents
Heart Rate
Pharmacology
Water

Keywords

  • Agiotensin
  • Angiotensin converting enzyme
  • Blood pressure
  • Genetic hypertension
  • Renin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Madeddu, P., Anania, V., Varoni, M. V., Parpaglia, P. P., Demontis, M. P., Fattaccio, M. C., ... Glorioso, N. (1995). Prevention by blockade of angiotensin subtype1-receptors of the development of genetic hypertension but not its heritability. British Journal of Pharmacology, 115(4), 557-562.

Prevention by blockade of angiotensin subtype1-receptors of the development of genetic hypertension but not its heritability. / Madeddu, P.; Anania, V.; Varoni, M. V.; Parpaglia, P. P.; Demontis, M. P.; Fattaccio, M. C.; Palomba, D.; Pollock, D.; Glorioso, N.

In: British Journal of Pharmacology, Vol. 115, No. 4, 1995, p. 557-562.

Research output: Contribution to journalArticle

Madeddu, P, Anania, V, Varoni, MV, Parpaglia, PP, Demontis, MP, Fattaccio, MC, Palomba, D, Pollock, D & Glorioso, N 1995, 'Prevention by blockade of angiotensin subtype1-receptors of the development of genetic hypertension but not its heritability', British Journal of Pharmacology, vol. 115, no. 4, pp. 557-562.
Madeddu, P. ; Anania, V. ; Varoni, M. V. ; Parpaglia, P. P. ; Demontis, M. P. ; Fattaccio, M. C. ; Palomba, D. ; Pollock, D. ; Glorioso, N. / Prevention by blockade of angiotensin subtype1-receptors of the development of genetic hypertension but not its heritability. In: British Journal of Pharmacology. 1995 ; Vol. 115, No. 4. pp. 557-562.
@article{cfe47ba691764f14b1b094969c36c941,
title = "Prevention by blockade of angiotensin subtype1-receptors of the development of genetic hypertension but not its heritability",
abstract = "1. We determined whether early inhibition of angiotensin II subtype, (AT1) receptors by the newly synthesized nonpeptidic antagonist, A-81988, can attenuate the development of hypertension in spontaneously hypertensive rats (SHR) and if the altered blood pressure phenotype can be passed on to the subsequent generation, not exposed to the antagonist. 2. Pairs of SHR were mated while drinking tap water or A-81988 in tap water, and the progeny was maintained on the parental regimen until 14 weeks of age. At this stage, A-81988-treated rats showed lower systolic blood pressure and body weight values (136 ± 5 versus 185 ± 4 mmHg and 247 ± 4 versus 283 ± 4 g in controls, P <0.01), while heart rate was similar. In addition, mean blood pressure was reduced (101 ± 7 versus 170 ± 7 mmHg in controls, P <0.01), and the presser responses to intravenous or intracerebroventricular angiotensin II were inhibited by 27 and 59{\%}, respectively. Heart/body weight ratio was smaller in A-81988-treated rats (3.2±0.1 versus 3.8±0.1 in controls, P<0.01). 3 The antihypertensive and antihypertrophic effect of A-81988 persisted in rats removed from therapy for 7 weeks (systolic blood pressure: 173±4 versus 220±4 mmHg, heart/body weight ratio: 3.41±0.1 versus 4.1±0.1 in controls at 21 weeks of age, P<0.01 for both comparisons), whereas the cardiovascular hypertensive phenotype was fully expressed in the subsequent generation that was maintained without treatment. 4. These results indicate that chronic blockade of angiotensin AT1-receptors attenuates the development of hypertension in SHR but it does not prevent the transmission of hypertension to the following generation. Thus, heritability of the SHR's hypertensive trait is not affected by pharmacological manipulation of the cardiovascular phenotype.",
keywords = "Agiotensin, Angiotensin converting enzyme, Blood pressure, Genetic hypertension, Renin",
author = "P. Madeddu and V. Anania and Varoni, {M. V.} and Parpaglia, {P. P.} and Demontis, {M. P.} and Fattaccio, {M. C.} and D. Palomba and D. Pollock and N. Glorioso",
year = "1995",
language = "English",
volume = "115",
pages = "557--562",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Prevention by blockade of angiotensin subtype1-receptors of the development of genetic hypertension but not its heritability

AU - Madeddu, P.

AU - Anania, V.

AU - Varoni, M. V.

AU - Parpaglia, P. P.

AU - Demontis, M. P.

AU - Fattaccio, M. C.

AU - Palomba, D.

AU - Pollock, D.

AU - Glorioso, N.

PY - 1995

Y1 - 1995

N2 - 1. We determined whether early inhibition of angiotensin II subtype, (AT1) receptors by the newly synthesized nonpeptidic antagonist, A-81988, can attenuate the development of hypertension in spontaneously hypertensive rats (SHR) and if the altered blood pressure phenotype can be passed on to the subsequent generation, not exposed to the antagonist. 2. Pairs of SHR were mated while drinking tap water or A-81988 in tap water, and the progeny was maintained on the parental regimen until 14 weeks of age. At this stage, A-81988-treated rats showed lower systolic blood pressure and body weight values (136 ± 5 versus 185 ± 4 mmHg and 247 ± 4 versus 283 ± 4 g in controls, P <0.01), while heart rate was similar. In addition, mean blood pressure was reduced (101 ± 7 versus 170 ± 7 mmHg in controls, P <0.01), and the presser responses to intravenous or intracerebroventricular angiotensin II were inhibited by 27 and 59%, respectively. Heart/body weight ratio was smaller in A-81988-treated rats (3.2±0.1 versus 3.8±0.1 in controls, P<0.01). 3 The antihypertensive and antihypertrophic effect of A-81988 persisted in rats removed from therapy for 7 weeks (systolic blood pressure: 173±4 versus 220±4 mmHg, heart/body weight ratio: 3.41±0.1 versus 4.1±0.1 in controls at 21 weeks of age, P<0.01 for both comparisons), whereas the cardiovascular hypertensive phenotype was fully expressed in the subsequent generation that was maintained without treatment. 4. These results indicate that chronic blockade of angiotensin AT1-receptors attenuates the development of hypertension in SHR but it does not prevent the transmission of hypertension to the following generation. Thus, heritability of the SHR's hypertensive trait is not affected by pharmacological manipulation of the cardiovascular phenotype.

AB - 1. We determined whether early inhibition of angiotensin II subtype, (AT1) receptors by the newly synthesized nonpeptidic antagonist, A-81988, can attenuate the development of hypertension in spontaneously hypertensive rats (SHR) and if the altered blood pressure phenotype can be passed on to the subsequent generation, not exposed to the antagonist. 2. Pairs of SHR were mated while drinking tap water or A-81988 in tap water, and the progeny was maintained on the parental regimen until 14 weeks of age. At this stage, A-81988-treated rats showed lower systolic blood pressure and body weight values (136 ± 5 versus 185 ± 4 mmHg and 247 ± 4 versus 283 ± 4 g in controls, P <0.01), while heart rate was similar. In addition, mean blood pressure was reduced (101 ± 7 versus 170 ± 7 mmHg in controls, P <0.01), and the presser responses to intravenous or intracerebroventricular angiotensin II were inhibited by 27 and 59%, respectively. Heart/body weight ratio was smaller in A-81988-treated rats (3.2±0.1 versus 3.8±0.1 in controls, P<0.01). 3 The antihypertensive and antihypertrophic effect of A-81988 persisted in rats removed from therapy for 7 weeks (systolic blood pressure: 173±4 versus 220±4 mmHg, heart/body weight ratio: 3.41±0.1 versus 4.1±0.1 in controls at 21 weeks of age, P<0.01 for both comparisons), whereas the cardiovascular hypertensive phenotype was fully expressed in the subsequent generation that was maintained without treatment. 4. These results indicate that chronic blockade of angiotensin AT1-receptors attenuates the development of hypertension in SHR but it does not prevent the transmission of hypertension to the following generation. Thus, heritability of the SHR's hypertensive trait is not affected by pharmacological manipulation of the cardiovascular phenotype.

KW - Agiotensin

KW - Angiotensin converting enzyme

KW - Blood pressure

KW - Genetic hypertension

KW - Renin

UR - http://www.scopus.com/inward/record.url?scp=0029050629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029050629&partnerID=8YFLogxK

M3 - Article

C2 - 7582472

AN - SCOPUS:0029050629

VL - 115

SP - 557

EP - 562

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 4

ER -